OR WAIT null SECS
Technologies to develop and manufacture biopharmaceuticals continue evolving
Technological advances are aiding manufacturers to streamline aseptic processes.
Quality Considerations for Using AI in Bio/Pharma
Sterile filtration and use of sterile single-use materials provide the best solutions depending on vector size.
November 06, 2024
Lonza’s Synnafix has licensed its ADC technology to BigHat Biosciences, which will combine it with its ML design platform to generate newly designed ADCs.
November 05, 2024
The expanded offices in Griesheim, Germany, feature a demonstration and training area.
October 31, 2024
The Novo Nordisk Foundation has committed DKK 600 million (US$87.4 million) towards the initial costs of the center housing the new supercomputer, which has the potential to accelerate drug discovery innovation.
October 30, 2024
The collaboration aims to develop precision genetic medicines using ViaNautis’ proprietary polyNaut technology platform.
Frontage Laboratories' Marianna Tcherpakov, PhD, director of Business Development, CMC Services, discussed the CDMO’s role in enabling startup biotechs solve complex technical challenges for scale up.
October 29, 2024
The company is investing $76 million to increase ADC manufacturing capacity at its St. Louis, Mo. facility.
October 28, 2024
Shannon Hinsdale from Revvity presented data at the Advancing Gene + Cell Therapies for Cancer conference demonstrating that base-editing systems are safe and effective for complex engineering in both T cells and iPSCs.
The companies expect to accelerate the clinical development of MRT-6160, a Phase I drug candidate, as well as explore further therapeutic opportunities across multiple indications.
October 24, 2024
Merck is acquiring the Yale-spinout, which develops direct DNA modification-enabled cancer treatments.
In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at CRB Group, discusses how facilities used for solid dosage manufacturing may be retrofitted into sustainable cell and gene therapy production facilities.
BioPharm International spoke with Kenneth LaRiviere, head of Engineering at Andelyn Biosciences, about the possible problems that can arise when operating an older facility for biopharmaceutical manufacturing.
Laks Pernenkil, Brian Feth, and Alex Philippidis go behind the headlines to discuss the impact of recent news, including FDA’s drug shortage list update, Nobel prize winners in microRNA and AI, and a big-potential research win for RNA editing.